FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
Platform Poised to Expand into Joint and Cartilage Repair
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has submitted a new patent application with the U.S. Patent and Trademark Office (USPTO) titled “Spheroids For Cartilage Repair” covering a proprietary fibroblast-derived therapy platform for use in orthopedic and musculoskeletal conditions, including degenerative disc repair, cartilage repair, and joint restoration.
The application, if granted, strengthens the protection for the Company’s novel fibroblast technology that leverages fibroblast cells, spheroids, and/or fibroblast-differentiated chondrocyte spheroids to support structural and functional repair in orthopedic tissues. Preclinical studies demonstrate that fibroblast-based constructs and chondrocyte spheroids integrate with native tissue, promote extracellular matrix remodeling, and encourage regeneration in models of disc degeneration and joint degeneration.
“This patent application represents an important step forward in expanding our vision of advancing fibroblast-based therapies from chronic wounds and immunology into the structural repair of the entire musculoskeletal system. If granted, this patent would provide broad protection for multiple therapeutic indications across orthopedics, positioning FibroBiologics to address large, underserved markets in degenerative disc disease, joint disease, trauma repair, and sports medicine,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. “The disease landscape is changing, and demand for regenerative orthopedic solutions is accelerating. Our platform has the potential to fundamentally change how we address cartilage loss and degenerative joint disease on a global scale. This is exactly the kind of long-term, high-impact opportunity our technology breakthroughs will allow us to pursue.”
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit .
For more information, please visit FibroBiologics' or email FibroBiologics at: .
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company’s intellectual property portfolio, the potential of FibroBiologics’ novel fibroblast technology, and the potential indications for FibroBiologics’ programs. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, . These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
General Inquiries:
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
